The breakpoint 16q24 has been described in AML with t(16;21)(q24;q22), which leads to the fusion gene RUNX1/MTG16 and is predominantly associated with therapy-related AML (41). This evidence concerns the gene RUNX1 and acute myeloid leukemia.